​

Evolus (EOLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EOLS Stock Forecast

Evolus (EOLS) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $24.00, with a high of $27.00 and a low of $20.00. This represents a 122.43% increase from the last price of $10.79.

$10 $14 $18 $22 $26 $30 High: $27 Avg: $24 Low: $20 Last Closed Price: $10.79

EOLS Stock Rating

Evolus stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

EOLS Price Target Upside V Benchmarks

TypeNameUpside
StockEvolus122.43%
SectorHealthcare Stocks 35.25%
IndustrySpecialty & Generic Drug Manufacturers Stocks47.55%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$24.00
Last Closing Price$10.79$10.79$10.79
Upside/Downside--122.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2533---6
Mar, 2543---7
Feb, 2543---7
Jan, 2543---7
Dec, 2443---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 03, 2024Douglas TsaoH.C. Wainwright$27.00$17.0558.36%150.23%
Sep 13, 2024Balaji PrasadBarclays$20.00$16.4621.51%85.36%
Sep 13, 2024Vamil DivanMizuho Securities$25.00$16.4651.88%131.70%
Jan 29, 2024Balaji PrasadBarclays$16.00$13.4718.78%48.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025BarclaysOverweightOverweighthold
Jan 27, 2025BarclaysOverweightOverweighthold
Oct 03, 2024H.C. WainwrightBuyBuyhold
Sep 13, 2024NeedhamBuyBuyhold
Sep 13, 2024BarclaysOverweightOverweighthold
Jan 29, 2024BarclaysOverweightupgrade
Jan 17, 2024NeedhamBuyBuyhold
Jun 24, 2022NeedhamBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.83$-0.94$-1.33$-1.08$-0.81----
Avg Forecast$-1.74$-0.97$-0.92$-0.56$-0.27$-0.04$0.77$1.57$2.64
High Forecast$-1.70$-0.95$-0.90$-0.48$-0.27$0.02$1.50$2.01$2.66
Low Forecast$-1.79$-1.00$-0.94$-0.62$-0.27$-0.10$0.37$0.93$2.62
Surprise %177.59%-3.09%44.57%92.86%200.00%----

Revenue Forecast

$50M $190M $330M $470M $610M $750M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$56.54M$99.67M$148.62M$202.09M$264.31M----
Avg Forecast$57.10M$99.77M$148.81M$201.28M$266.30M$351.27M$465.53M$592.49M$713.10M
High Forecast$58.33M$101.92M$151.37M$201.41M$267.18M$353.98M$468.07M$593.01M$718.39M
Low Forecast$55.99M$97.83M$146.27M$201.14M$264.55M$349.42M$462.99M$591.96M$709.15M
Surprise %-0.98%-0.09%-0.13%0.40%-0.75%----

Net Income Forecast

$-200M $-120M $-40M $40M $120M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-163.01M$-46.81M$-74.41M$-61.69M$-50.42M----
Avg Forecast$-99.11M$-55.46M$-90.92M$-61.69M$-15.39M$-2.47M$25.62M$83.66M$150.12M
High Forecast$-96.60M$-54.05M$-72.74M$-49.35M$-15.26M$908.70K$85.59M$114.67M$151.57M
Low Forecast$-101.89M$-57.01M$-109.11M$-74.02M$-15.52M$-5.84M$20.79M$52.75M$149.04M
Surprise %64.48%-15.59%-18.16%-227.69%----

EOLS Forecast FAQ

Is Evolus stock a buy?

Evolus stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evolus is a favorable investment for most analysts.

What is Evolus's price target?

Evolus's price target, set by 11 Wall Street analysts, averages $24 over the next 12 months. The price target range spans from $20 at the low end to $27 at the high end, suggesting a potential 122.43% change from the previous closing price of $10.79.

How does Evolus stock forecast compare to its benchmarks?

Evolus's stock forecast shows a 122.43% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the specialty & generic drug manufacturers stocks industry (47.55%).

What is the breakdown of analyst ratings for Evolus over the past three months?

  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Evolus’s EPS forecast?

Evolus's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.04, marking a -95.06% decrease from the reported $-0.81 in 2024. Estimates for the following years are $0.77 in 2026, $1.57 in 2027, and $2.64 in 2028.

What is Evolus’s revenue forecast?

Evolus's average annual revenue forecast for its fiscal year ending in December 2025 is $351.27M, reflecting a 32.90% increase from the reported $264.31M in 2024. The forecast for 2026 is $465.53M, followed by $592.49M for 2027, and $713.1M for 2028.

What is Evolus’s net income forecast?

Evolus's net income forecast for the fiscal year ending in December 2025 stands at $-2.466M, representing a -95.11% decrease from the reported $-50.42M in 2024. Projections indicate $25.62M in 2026, $83.66M in 2027, and $150.12M in 2028.